Shenzhen Kangtai Biological Products Co. Ltd. Class A

Shenzhen Kangtai Biological Products Co. Ltd. Class A

SSZSE:300601
11.43
CNY
-0.19
(-1.64%)
0.10EPS
130.01P/E
15.17BMarket Cap
Apr 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.28
0.37
0.51
0.61
1.18
2.03
1.92
2.14
5.35
2.86
3.11
2.37
2.28
2.2
Basic EPS, GAAP
- -
0.04
0.07
0.1
0.22
0.44
0.57
0.64
1.85
-0.12
0.77
0.18
0.06
0.1
Free Cash Flow per Basic Share
-0.11
0.03
0.18
-0.1
-0.04
-0.01
0.12
-0.75
-1.3
-0.69
0.28
0.12
0.26
- -
Dividend per Share
0.04
0.04
0.03
0.02
0.04
0.06
0.18
0.2
0.32
0.56
0.21
0.23
0.11
0.07
Book Value per Share
0.44
0.66
0.73
0.83
1.06
1.8
2.67
6.81
8.34
8.02
8.54
8.65
8.62
8.67
Tangible Book Value per Share
0.24
0.47
0.53
0.61
0.85
1.6
2.31
6.48
7.67
7.6
8.09
8.17
8.1
7.99
Basic Weighted Avg Shares
905
830
885
898
982
996
1,010
1,055
683
1,106
1,119
1,120
1,172
1,116
Sales/Revenue/Turnover
251
303
453
552
1,161
2,017
1,943
2,261
3,652
3,157
3,477
2,652
2,673
2,450
Operating Margin (%)
-0.37
20.24
17.24
19.27
22.47
24.95
34.05
32.51
41.86
18.78
31.01
17.9
9.4
10.48
Depreciation Expense
48
49
50
46
58
58
83
93
405
201
201
317
400
- -
Net Income, GAAP
2
31
63
86
215
436
575
679
1,263
-133
861
202
70
117
Effective Tax Rate (%)
- -
9.59
11.63
12.9
9.78
10.92
13.41
12.07
12.22
- -
8.4
- -
- -
7.47
Profit Margin (%)
0.6
10.27
13.88
15.62
18.49
21.6
29.56
30.04
34.59
-4.2
24.77
7.6
2.63
4.76
Working Capital
115
204
146
170
213
771
958
3,589
4,723
2,835
2,645
3,595
3,779
4,218
LT Debt
375
272
188
281
227
413
195
68
1,938
2,016
2,372
1,786
1,870
1,932
Total Equity
372
584
647
735
1,071
1,837
2,754
7,463
9,167
8,985
9,542
9,661
9,632
9,710
Return on Invested Capital (%)
- -
3.4
6.27
7.61
17.99
23.49
21.64
12.19
12.64
- -
7.46
- -
- -
0.9
Return on Capital (%)
- -
5.18
7.23
8.82
17.7
24.95
21.93
12.9
13.48
- -
8.29
- -
- -
2
Return on Common Equity (%)
0.38
6.52
10.21
12.48
23.78
29.96
25.03
13.29
15.19
-1.46
9.3
2.1
0.73
1.21

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
37
46
19
LT Borrowings
1,890
1,911
1,932
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,117
1,117
1,117
Market Capitalization
15,536
12,666
15,168

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,957
6,205
6,211
Cash, Cash Equivalents & STI
1,881
2,146
2,358
Accounts Receivable, Net
2,752
2,740
2,625
Inventories
694
683
681
Total Current Liabilities
2,075
2,031
1,992
Payables & Accruals
- -
- -
- -
ST Debt
37
46
19
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.97%
5.6%
-0.3%
Free Cash Flow
-287.87%
-13.77%
131.67%
Net Income, GAAP
-57.59%
-183.04%
-65.12%
Sales/Revenue/Turnover
25.38%
7.03%
0.81%
Total Cash Common Dividend
44.38%
17.23%
-48.74%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
452
750
816
634
2,652
2025
645
747
- -
610
2,673
2026
631
642
568
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.1
0.17
-0.13
0.18
2025
0.02
0.01
- -
0.02
0.06
2026
0.03
0.02
0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.2
0.02
- -
0.23
2025
- -
0.09
- -
- -
0.11
2026
- -
0.04
0.03
- -
- -

Company Description

CEO
Xiang Miao
Full Time Employees
1,957
Sector
Health technology
Industry
Biotechnology
Address
Kangtai Group Building Shenzhen GD China 518057
IPO Date
Feb 7, 2017
Business
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) engages primarily in the research, development, production, and sales of human vaccines in China. The company offers a portfolio of marketed vaccines including recombinant hepatitis B vaccines in 10ug, 20ug, and 60ug doses (world's first 60-microgram formulation), 13-valent pneumococcal polysaccharide conjugate vaccines (dual-carrier), 23-valent pneumococcal polysaccharide vaccines, Haemophilus influenzae type b (HIB) conjugate vaccines, diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b combined vaccines, cell-free whitebait b-type Haemophilus influenzae combined vaccines, measles-rubella combined vaccines, SARS-CoV-2 vaccines, freeze-dried varicella vaccines, and four-dose human diploid cell rabies vaccines; its research and development pipeline encompasses rabies vaccines for human use, inactivated poliomyelitis vaccines, live attenuated varicella vaccines, and platforms for live attenuated viral vaccines, inactivated viral vaccines, recombinant protein vaccines, bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, combination vaccines, viral vector vaccines, mRNA vaccines, and new adjuvant technologies. Founded in 1992 and headquartered in Shenzhen, China, the company operates five major R&D and industrial bases in Shenzhen and Beijing, with a marketing network spanning 31 provinces, autonomous regions, and municipalities in China, targeting public health needs across infant, pediatric, adult, and high-risk populations. In a key recent development, Shenzhen Kangtai formed a 50-50 joint venture with AstraZeneca in April 2025 in the Beijing Economic-Technological Development Area to research, develop, and produce innovative vaccines, with registered capital of RMB 345 million and total investment of approximately USD 400 million, marking AstraZeneca's first vaccine production hub in China and enhancing the company's global reach for Chinese and emerging markets.